Forma Therapeutics, Inc. clinical trials
Acquired by Novo Nordisk A/S, Oct 14, 2022 · source ↗
The registry lists 10 studies whose lead sponsor is Forma Therapeutics, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 18, 2026.
Before and after it joined Novo Nordisk A/S
- First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- 8
- First submitted after Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Forma Therapeutics, Inc.10 studies
Something wrong with this grouping? Tell us on the Novo Nordisk A/S page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Novo Nordisk A/S studies →
- A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseRecruitingNCT06198712Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted after Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeRecruitingNCT05953584Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted after Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT05568225Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationCompletedNCT02719574Phase 1/2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 3
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic SteatohepatitisTerminatedNCT04004325Phase 1/2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsCompletedNCT03815695Phase 1
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationCompletedNCT03684811Phase 1/2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted before Forma Therapeutics, Inc. became part of Novo Nordisk A/S